Beyond GCT, CLDN6 would be also a suitable target for other CLDN6+ tumor entities, such as myeloid leukemia, ovarian, endometrial, or urothelial carcinoma (Zhang et al. 2021). This evidence concerns the gene CLDN6 and granular cell tumor.